CYP19A1 and breast carcinoma: Endocrine therapies—namely, tamoxifen and aromatase inhibitors—reduce the risk of reoccurrence of breast cancer in patients diagnosed as having oestrogen receptor and/or progesterone receptor positive breast cancer following surgery (adjuvant treatment).